Research Update: J.P. Morgan Chase & Co. Outlook Revised To Positive From Stable May 06

  • ID: 2041609
  • May 2006
  • Standard & Poors
1 of 3

On May 3, 2006, Standard & Poor's Ratings Services revised the outlook on its 'A+/A-1' ratings on J.P. Morgan Chase & Co. (JPM) and its 'AA-/A-1+' ratings on JPM's operating unit JPMorganChase Bank N.A. to positive from stable JPM has the potential to perform better than it currently is, with a portfolio of businesses that enjoy leading positions in the industry. The rating has been held down by the volatility of the performance of the investment bank and the weak profitability of its consumer businesses; however, the performance issues are being addressed. The card business is demonstrating some growth, and the investments in the retail branch system should bear fruit over the next year or so. The most recent quarter...

Companies mentioned in this report are:
- JPMorgan Chase & Co.

Action: Outlook: Positive

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Product Type: Research Update
Research updates complement media releases. They offer more depth and detail than summary analyses by incorporating all information published in the media release. They are more up to date than summaries in that they are published simultaneously with media releases.

Note: Product cover images may vary from those shown
2 of 3

- JPMorgan Chase & Co.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.